Advertisement

Topics

Europe expands approved indication of Amgen's Repatha in cardiovascular disease

06:14 EDT 17 May 2018 | Pharmafile

Amgen has revealed that its PCSK9 inhibitor Repatha (evolocumab) has received approval from the European Commission in a new indication: to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels in adult patients with established atherosclerotic cardiovascular disease, such as myocardial infarction, stroke or peripheral arterial disease.

read more

Original Article: Europe expands approved indication of Amgen's Repatha in cardiovascular disease

NEXT ARTICLE

More From BioPortfolio on "Europe expands approved indication of Amgen's Repatha in cardiovascular disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...